Overview

Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2019-07-04
Target enrollment:
Participant gender:
Summary
This is an open-label, combined 2-part multicenter study to evaluate the efficacy, safety, and tolerability of blinatumomab in adult and pediatric Japanese patients with relapsed/refractory B-precursor ALL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Amgen
Collaborator:
Amgen Astellas Biopharma K.K.
Treatments:
Antibodies, Bispecific
Blinatumomab